BBHC
SAGE

Brown Brothers Harriman & Co’s Sage Therapeutics SAGE Stock Holding History

Brown Brothers Harriman & Co’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5
Closed -$1K – 1259
2019
Q3 		$1K Sell
5
-25
-83% -$4.18K ﹤0.01% 1151
2019
Q2 		$5K Buy
+30
New +$5.12K ﹤0.01% 897
2017
Q1 		– Sell
-92
Closed -$5K – 866
2016
Q4 		$5K Hold
92
– – ﹤0.01% 765
2016
Q3 		$4K Hold
92
– – ﹤0.01% 712
2016
Q2 		$3K Buy
+92
New +$3.07K ﹤0.01% 766

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Brown Brothers Harriman & Co's SAGE Position: Q4 2019 in Review

Brown Brothers Harriman & Co sold out of Sage Therapeutics (SAGE) in Q4 2019, closing a stake of 5 shares — an estimated $1K sold.

Brown Brothers Harriman & Co first reported a position in SAGE in Q2 2016 and held it in 5 quarters. The position peaked at $5K in Q2 2019. 266 funds tracked by Wall St. Rank hold SAGE as of Q4 2019.

  • Brown Brothers Harriman & Co reported no remaining Sage Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 5 Sage Therapeutics shares in Q4 2019, an estimated $1K.
  • Brown Brothers Harriman & Co first reported a position in Sage Therapeutics in Q2 2016 and held it in 5 quarters.
  • Brown Brothers Harriman & Co's Sage Therapeutics position peaked at $5K in Q2 2019.
  • 266 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2019.

Based on Brown Brothers Harriman & Co's 13F filing for Q4 2019, filed 14 Feb 2020.